CW June 2005
Volume 14Issue Number 6 June 2005 ISSN 10593802 Adding Bevacizumab Improves Response RatesA metastatic colorectal cancer clinical trial (TREE-2) adding bevacizumab (Avastin, Genentech) to each of 3 chemotherapy regimens tested in a prior trial (TREE-1) found the addition of bevacizumab to be well tolerated and to improve overall response rate (ORR) in each case. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor.
Go to Previous Page Go to Next Page Source & Additional Reading Professor Howard S. Hochster, New York University School of Medicine, New York, NY. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
